{"id":53049,"date":"2023-01-18T18:02:43","date_gmt":"2023-01-18T17:02:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/15th-annual-biotech-showcase-brings-together-one-of-the-largest-most-informative-in-person-biotech-investment-conferences\/"},"modified":"2023-01-18T18:02:43","modified_gmt":"2023-01-18T17:02:43","slug":"15th-annual-biotech-showcase-brings-together-one-of-the-largest-most-informative-in-person-biotech-investment-conferences","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/15th-annual-biotech-showcase-brings-together-one-of-the-largest-most-informative-in-person-biotech-investment-conferences\/","title":{"rendered":"15th Annual Biotech Showcase\u2122 Brings Together One Of The Largest, Most Informative In-Person Biotech Investment Conferences"},"content":{"rendered":"
\n

\nGlobal Life Science Executives and Investors Met Last Week to Forecast Year Ahead<\/i>\n<\/p>\n

NEW YORK & CARLSBAD, Calif.–(BUSINESS WIRE)–In its 15th<\/sup> year, Biotech Showcase\u2122<\/b><\/a>, co-produced by Demy-Colton<\/a> and EBD Group<\/a>, welcomed more than 3,200 attendees, more than 1,100 investors, and more than 400 presenting companies. Following a 2-year shift to virtual, the conference was held in-person in San Francisco from January 9-11, 2023, for the first time since 2020, with a virtual partnering component the following week from January 18-19. The event allowed attendees to explore impactful trends, engage industry experts, discover innovative companies, and meet motivated investors. Among attendees were nearly 70 members of the press.\n<\/p>\n

<\/a><\/p>\n

\nIn an annual event meant to drive the future of drug discovery and development, this year\u2019s participants engaged in 24 program sessions and panels, which included more than 115 speakers. Attendees also engaged in more than 7,000 partnering meetings delivered through the partneringONE\u00ae<\/b><\/a> meeting platform.\n<\/p>\n

\nThe 2023 program featured insights from top investors and biopharma executives across a broad spectrum of expertise. Speakers examined numerous relevant topics, from how COVID-19 accelerated all things digital, to the biopharma industry advancing drug discovery and manufacturing to improve patient outcomes, and provided updates in critical therapeutic areas such as CNS, cell and gene therapy, women\u2019s health, and oncology. The full agenda is available here<\/a>. Some especially timely topics related to current economic forces and industry change, including:\n<\/p>\n